StockNews.AI
DMAC
StockNews.AI
3 days

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

1. DMAC's CEO and CBO will participate in a healthcare conference. 2. The conference takes place in New York from September 3-5, 2025. 3. Management will meet with investors for one-on-one discussions. 4. DMAC focuses on treatments for serious ischemic diseases. 5. DM199 is their lead candidate for treating ischemic stroke.

6m saved
Insight
Article

FAQ

Why Bullish?

Investor engagement at conferences typically increases stock interest and visibility.

How important is it?

Increased visibility and investor engagement can lead to short-term price appreciation.

Why Short Term?

The conference is imminent and could attract investors quickly.

Related Companies

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025.

Fireside Chat Details

Date & Time: Thursday, September 4, 2025 | 9:10-9:40 am ET

Location: New York Marriott Marquis - 1535 Broadway, New York, NY 10036

Moderator: Joshua Schimmer, Managing Director, Biotech Equity Research Analyst, Cantor Fitzgerald

Webcast: Click here to access the live presentation

Management will also be available for one-on-one meetings with investors during the conference.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diamedica.com.

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306

mmoyer@lifesciadvisors.com

Media Contact:

Madelin Hawtin

LifeSci Communications

mhawtin@lifescicomms.com

Related News